Pediatric preclinical testing consortium evaluation of the EZH2 inhibitor tazemetostat in orthotopic PDX models of pediatric brain tumors.

被引：1
|
作者：
Li, Xiao-Nan
Qi, Lin
Kogiso, Mari
Lindsay, Holly Brianne
Erickson, Stephen W.
Guo, Yuelong
Smith, Malcolm A.
Teicher, Beverly A.
机构：
[1] Baylor Coll Med, Program Preclin Neuro Oncol Res, Texas Childrens Canc Ctr, Lab Mol Neuro Oncol, Houston, TX 77030 USA
[2] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA
[3] RTI Int, Res Triangle Pk, NC USA
[4] NCI, Canc Therapy Evaluat Program, Washington, DC USA
[5] NIH, NCI, Bldg 10, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.10551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10551
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Pediatric Preclinical Testing Consortium Evaluation of the MCL1 Inhibitor, AMG 176, Against Xenograft Models of Acute Lymphoblastic Leukemia
    Lock, Richard B.
    Evans, Kathryn
    Watts, Ben
    Randall, Joanna
    Toscan, Cara E.
    Earley, Eric J.
    Erickson, Stephen W.
    Belmontes, Brian
    Wong, Philip
    Teicher, Beverly A.
    Hughes, Paul E.
    Smith, Malcolm A.
    BLOOD, 2022, 140 : 11690 - 11691
  • [22] Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium
    Gill, Jonathan
    Zhang, Wendong
    Zhang, Zhongting
    Roth, Michael
    Harrison, Douglas J.
    Rowshan, Sudie
    Erickson, Stephen
    Gatto, Gregory
    Kurmasheva, Raushan
    Houghton, Peter
    Teicher, Beverly
    Smith, Malcolm A.
    Kolb, E. Anders
    Gorlick, Richard
    PEDIATRIC BLOOD & CANCER, 2020, 67 (10)
  • [23] MOLECULAR CHARACTERIZATION OF ORTHOTOPIC PATIENT-DERIVED XENOGRAFT MODELS OF PEDIATRIC BRAIN TUMORS AND THEIR USE IN PRECLINICAL EXPERIMENTS
    Brabetz, Sebastian
    Schmidt, Christin
    Groebner, Susanne N.
    Mack, Norman
    Seker-Cin, Huriye
    Jones, David T. W.
    Chavez, Lukas
    Milde, Till
    Witt, Olaf
    Leary, Sarah E.
    Li, Xiao-Nan
    Wechsler-Reya, Robert J.
    Olson, James M.
    Pfister, Stefan M.
    Kool, Marcel
    NEURO-ONCOLOGY, 2017, 19 : 49 - 49
  • [24] Phase 1 Study of Tazemetostat, An Enhancer of Zeste Homolog-2 (EZH2) Inhibitor, In Pediatric Patients With Relapsed/Refractory Integrase Interactor 1 (INI1)-Negative Tumors
    Chi, S.
    Bourdeaut, F.
    Laetsch, T.
    Fouladi, M.
    Macy, M.
    Makin, G.
    Shukla, N.
    Wetmore, C.
    Margol, A.
    Casanova, M.
    Kilburn, L.
    Yi, J.
    Hargrave, D.
    Mccowage, G.
    Pinto, N.
    Ebb, D.
    Robinson, G.
    Sierra, L.
    Merchant, M.
    Nysom, K.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S123 - S124
  • [25] Molecular analysis of solid tumors (MAST): A protocol for comprehensive preclinical evaluation of pediatric solid tumors.
    Federico, Sara Michele
    Stewart, Elizabeth
    Bradley, Cori
    McEvoy, Justina
    Loh, Amos
    Shelat, Anang
    Zhang, Jinghui
    Chen, Xiang
    Pappo, Alberto S.
    Dyer, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3
    Wiese, M.
    Schill, F.
    Sturm, D.
    Pfister, S.
    Hulleman, E.
    Johnsen, S. A.
    Kramm, C. M.
    KLINISCHE PADIATRIE, 2016, 228 (03): : 113 - 117
  • [27] Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium
    Kurmasheva, Raushan T.
    Bandyopadhyay, Abhik
    Favours, Edward
    Del Pozo, Vanessa
    Ghilu, Samson
    Phelps, Doris A.
    McGeehan, Gerard M.
    Erickson, Stephen W.
    Smith, Malcolm A.
    Houghton, Peter J.
    PEDIATRIC BLOOD & CANCER, 2020, 67 (07)
  • [28] Pharmacokinetics of lonafarnib, a farnesyl protein transferase inhibitor, in pediatric patients with brain tumors.
    Zhu, Y
    Statkevich, P
    Curtis, D
    Sugrue, M
    Kieran, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P10 - P10
  • [29] TRANSGLUTAMINASE 2 EXPRESSION AND INDUCED CHEMORESISTANCE IN PEDIATRIC BRAIN TUMORS.
    Schooler, Kevin P.
    Dyer, Lisa
    Brown, Kevin
    CRITICAL CARE MEDICINE, 2008, 36 (12) : A25 - A25
  • [30] Evaluation of the TPO-receptor agonist Eltrombopag in the Pediatric Preclinical Testing Consortium osteosarcoma in vivo models.
    Roth, Michael
    Nevil, Grace
    Gill, Jonathan Benjamin
    Zhang, Wendong
    Teicher, Beverly A.
    Erickson, Stephen W.
    Gatto, Gregory
    Smith, Malcolm A.
    Kolb, E. Anders
    Gorlick, Richard Greg
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345